Vitamin D supplementation in polymorphic light eruption: Randomized double-blinded placebo-controlled trial - Vitamin D and PLE

Medizinische Universität Graz, Univ. Klinik Dermatologie, Forschungseinheit für Photodermatologie0 个研究点开始时间: 2012年3月6日最近更新: 2016年9月5日

适应症

试验速览

暂无简介。

•age greater than 18 years and below 75 years
•confirmed diagnosis of polymorphic light eruption by typical patient history and/or typical histology of skin lesions and/or positive photoprovocation results
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 36
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Allergy or intolerance to Oleovit Vitamin D3 or Coconut
•presence or history of malignant skin tumors,
•dysplastic melanocytic nevus syndrome,
•photosensitive diseases such as porphyria, chronic actinic dermatitis, xeroderma pigmentosum, basal cell nevus syndrome;
•renal dysfunction, Sarcoid,
•autoimmune disorders such as lupus erythematosus or dermatomyositis, psychiatric disorders, pregnancy or breast feeding, antinuclear antibodies such as anti-ds-DNA or anti-Ro/La, topical treatment with vitamin D derivates within 3 months, oral treatment with vitamin D within 6 months, 25-OH vitamin D levels > 30 ng/ml at screening visit, systemic treatment with steroids and/or other immunosuppressive drugs within 4 weeks, UV exposure in test fields within 8 weeks before the start of the study, general poor health status, treatment with thiazides or glycosides, serum hypercalcemia > 2,65 nmol/l

发起方

Medizinische Universität Graz, Univ. Klinik Dermatologie, Forschungseinheit für Photodermatologie